Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
140.84(c) 143.16(c) 140.24(c) 140.46(c) 139.02(c) Last
897 415 1 389 505 1 353 172 1 436 254 2 064 407 Volume
+0.16% +1.65% -2.04% +0.16% -1.03% Change
More quotes
Financials ($)
Sales 2017 3 524 M
EBIT 2017 1 492 M
Net income 2017 551 M
Debt 2017 1 294 M
Yield 2017 -
Sales 2018 4 094 M
EBIT 2018 1 933 M
Net income 2018 1 075 M
Finance 2018 298 M
Yield 2018 -
P/E ratio 2017 57,65
P/E ratio 2018 29,55
EV / Sales2017 9,26x
EV / Sales2018 7,58x
Capitalization 31 349 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
10/26 | 12:30pmEarnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
10/14 ALEXION INVESTIGATION INITIATED BY F : Kahn Swick & Foti, LLC Investigates the O..
10/12 ALEXION PHARMACEUTICALS : to Report Third Quarter 2017 Results On Thursday, Octo..
10/10 ALEXION PHARMACEUTICALS : to Report Third Quarter 2017 Results on Thursday, Octo..
10/07 ALEXION INVESTIGATION INITIATED BY F : Kahn Swick & Foti, LLC Investigates the O..
09/30 ALEXION INVESTIGATION INITIATED BY F : Kahn Swick & Foti, LLC Investigates the O..
09/26 ROBBINS ARROYO LLP : Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders Ac..
09/19 ALEXION PHARMACEUTICALS : Adds Paul A. Friedman, M.D. To Its Board of Directors
09/19 ALEXION PHARMACEUTICALS : Lupin appoints Jim Loerop to drive M&A, business devel..
09/18 ALEXION PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
09/14 ALEXION PHARMACEUTICALS : Adds Paul A. Friedman, M.D. to Its Board of Directors
More news
Sector news : Biopharmaceuticals
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Biopharmaceuticals
Latest Tweets
01:36aAlexion Pharmaceuticals, Inc. $ALXN Expected to Post Quarterly Sales of $866... 
10/20$ALXN is Bullish above $138.76. Trade near $138.76  
10/20SWING TRADE ALERT: Recent $ALXN technical alerts: Crossed Above 50 DMA plus 1.. 
10/19$ALXN - FY2017 EPS Estimates for Alexion Pharmaceuticals, Inc. #ALXN Reduced .. 
10/19Alexion Pharmaceuticals $ALXN Receives Media Sentiment Score of 0.10  
More tweets
Qtime:103
News from SeekingAlpha
10/11 YOUR DAILY PHARMA SCOOP : Alexion's Catalysts, Amgen's Prolia, Ultragenyx Borosu..
10/10 An In-Depth Look At Alexion's Competition And Upcoming Catalysts
10/08 ALEXION : Buy On Dips With Soliris Catalyst Upcoming
10/05 YOUR DAILY PHARMA SCOOP : The First Trust NYSE Arca Biotechnology Index, Gilead'..
10/02 YOUR DAILY PHARMA SCOOP : Alexion's Canada Pricing, Zogenix, RedHill, Flexion
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 163 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
Paul J. Clancy Chief Financial Officer
John J. Orloff Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS14.80%31 299
BIOGEN31.85%72 855
CSL LIMITED38.38%50 210
GRIFOLS SA30.11%18 008
BIOMARIN PHARMACEUTICAL6.98%15 532
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 711